Genmab
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
- Conditions
- Malignant Solid Tumor
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Genmab
- Target Recruit Count
- 42
- Registration Number
- NCT06057038
- Locations
- 🇯🇵
National Cancer Center East, Kashiwa, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
🇯🇵Tokyo Medical University Hospital, Tokyo, Japan
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
- Conditions
- Advanced Endometrial Cancer
- Interventions
- Biological: PembrolizumabBiological: Acasunlimab
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Genmab
- Registration Number
- NCT06046274
- Locations
- 🇺🇸
Orlando Health Cancer Institute, Orlando, Florida, United States
🇺🇸Rudgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇧🇪Cliniques Universitaires Saint-Luc, Brussel, Belgium
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
- Conditions
- Classical Hodgkin LymphomaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Genmab
- Target Recruit Count
- 9
- Registration Number
- NCT06018129
- Locations
- 🇺🇸
City of Hope Helford Clinical Research Hospital, Duarte, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Expanded Access Program for Epcoritamab
- Conditions
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)Grade 3B Follicular LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedLarge B-cell LymphomaHigh Grade B-cell Lymphoma (HGBCL)
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Genmab
- Registration Number
- NCT05733650
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 180
- Registration Number
- NCT05660967
- Locations
- 🇺🇸
UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States
🇦🇹Kepler Universitätsklinikum, Linz, Austria
🇦🇹LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 26
- Registration Number
- NCT05586321
- Locations
- 🇬🇪
ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia
🇲🇩ARENSIA Exploratory Medicine Phase I Unit, Chisinau, Moldova, Republic of
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Genmab
- Target Recruit Count
- 900
- Registration Number
- NCT05578976
- Locations
- 🇺🇸
University of Arizona Cancer Center - North Campus /ID# 227463, Tucson, Arizona, United States
🇺🇸Yuma Regional Medical Center /ID# 261527, Yuma, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences /ID# 225703, Little Rock, Arkansas, United States
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
- Conditions
- Non-CNS Tumor
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 88
- Registration Number
- NCT05491317
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷Centre Leon Berard, Lyon, France
🇫🇷Institut Gustave Roussy, Villejuif, France
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
- Conditions
- Classic Follicular LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Genmab
- Target Recruit Count
- 184
- Registration Number
- NCT05451810
- Locations
- 🇺🇸
Infirmary Health - Infirmary Cancer Care at Mobile Infirmary /ID# 264630, Mobile, Alabama, United States
🇺🇸University of Arkansas for Medical Sciences /ID# 244562, Little Rock, Arkansas, United States
🇺🇸Highlands Oncology Group, PA /ID# 245002, Springdale, Arkansas, United States
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Genmab
- Target Recruit Count
- 31
- Registration Number
- NCT05435339
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇪🇸Clinica Universidad de Navarra, Pamplona, Navarra, Spain